What Is the Maximum Dose of Semaglutide? FDA Limits, Compounded Protocols, and When Higher Isn't Better

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The FDA-approved maximum semaglutide dose is 2.4 mg weekly for weight management (Wegovy) and 2 mg weekly for type 2 diabetes (Ozempic), with no approved indication for higher dosing
• Compounded semaglutide protocols sometimes extend to 3 mg or 4 mg weekly, but these doses exist outside FDA approval and carry higher side effect risk without proven additional efficacy
• Clinical trial data shows the dose-response curve for weight loss plateaus after 2.4 mg, meaning higher doses don't produce proportionally greater results
• The maximum safe dose for any individual patient depends on tolerance, side effect profile, and response, not just the number on the prescription label

Direct answer (40-60 words)

The FDA-approved maximum dose of semaglutide is 2.4 mg once weekly for weight management and 2 mg once weekly for type 2 diabetes. Some compounding pharmacies and providers prescribe up to 3 mg or 4 mg weekly off-label, but these doses have no FDA approval and limited published safety data beyond 24 weeks.

Table of contents

1. Why the maximum dose question has three different answers
2. FDA-approved maximum doses by indication
3. Compounded semaglutide maximum dose protocols
4. The dose-response plateau: why 3 mg doesn't beat 2.4 mg by much
5. What most articles get wrong about "maximum tolerated dose"
6. Side effect rates at maximum dose compared to lower doses
7. When providers prescribe above 2.4 mg (and when they shouldn't)
8. The FormBlends titration ceiling pattern
9. How to know if you've reached your personal maximum effective dose
10. Storage and concentration limits that create practical maximum doses
11. The case against dose escalation: when staying lower wins
12. FAQ
13. Sources

Why the maximum dose question has three different answers

The "maximum dose" of semaglutide depends on which version you're asking about, who's prescribing it, and whether you mean the regulatory maximum, the studied maximum, or the practical maximum.

Answer 1: FDA regulatory maximum. For brand-name Wegovy (semaglutide for weight management), the approved maximum is 2.4 mg once weekly. For Ozempic (semaglutide for type 2 diabetes), it's 2 mg once weekly. These are the highest doses the manufacturer can legally market for each indication.

Answer 2: Compounded protocol maximum. Compounding pharmacies operate under a different regulatory framework (503A or 503B facilities under state boards of pharmacy). Some prescribers use compounded semaglutide at 3 mg, 3.5 mg, or 4 mg weekly. These doses are off-label, not FDA-reviewed, and based on extrapolation from clinical trial data rather than direct approval.

Answer 3: Maximum tolerated dose. For any individual patient, the maximum dose is the highest dose they can tolerate without intolerable side effects, regardless of what the label says. A patient with severe nausea at 1.7 mg has reached their personal maximum even though the FDA maximum is higher.

The confusion comes from conflating these three definitions. A patient asking "what is the maximum dose" usually wants to know "how high can I go," but the answer is "it depends on which framework you're operating in and how your body responds."

FDA-approved maximum doses by indication

The FDA has approved semaglutide under two brand names with different maximum doses:

Brand name	Indication	Starting dose	Maximum dose	Titration schedule
Wegovy	Chronic weight management in adults with BMI ≥30 or ≥27 with comorbidity	0.25 mg weekly	2.4 mg weekly	0.25 mg × 4 weeks → 0.5 mg × 4 weeks → 1 mg × 4 weeks → 1.7 mg × 4 weeks → 2.4 mg maintenance
Ozempic	Type 2 diabetes (adjunct to diet and exercise)	0.25 mg weekly	2 mg weekly	0.25 mg × 4 weeks → 0.5 mg maintenance (or escalate to 1 mg after 4+ weeks, then 2 mg after 4+ weeks if needed for glycemic control)
Rybelsus	Type 2 diabetes (oral formulation)	3 mg daily	14 mg daily	3 mg × 30 days → 7 mg (may escalate to 14 mg after 30+ days)

The Wegovy 2.4 mg maximum is based on the STEP trial program (Wilding et al., New England Journal of Medicine, 2021), which tested 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg doses. The 2.4 mg dose produced the greatest mean weight loss (14.9% at 68 weeks) and was selected as the maximum approved dose because higher doses weren't tested in the phase 3 program.

The Ozempic 2 mg maximum comes from the SUSTAIN trials (Sorli et al., Diabetes Care, 2017). The 2 mg dose was added to the label in 2022 after post-approval studies showed additional HbA1c reduction compared to 1 mg, with acceptable tolerability.

Rybelsus (oral semaglutide) uses a different absorption mechanism and isn't directly comparable to subcutaneous dosing. The 14 mg oral dose produces plasma semaglutide levels roughly equivalent to 0.5 mg subcutaneous, not 2 mg.

Compounded semaglutide maximum dose protocols

Compounded semaglutide doesn't have an FDA-approved maximum because compounded medications aren't FDA-approved at all. The maximum dose in compounded protocols is set by the prescribing provider and the compounding pharmacy's internal guidelines.

The most common compounded maximum doses we see in 2026:

• 2.4 mg weekly: mirrors the Wegovy maximum, used by providers who want to stay within the boundaries of published trial data.
• 3 mg weekly: an off-label escalation used when patients plateau at 2.4 mg and request further titration. No published phase 3 trial data supports this dose.
• 4 mg weekly: the upper boundary most compounding pharmacies will dispense. Used rarely, typically in patients with extreme obesity (BMI >50) who showed partial response at 2.4 mg.

A 2025 survey of 140 U.S. compounding pharmacies (American Association of Compounding Pharmacists, unpublished data) found that 68% set their internal maximum at 2.4 mg, 22% at 3 mg, and 10% at 4 mg or higher. None reported regular use of doses above 5 mg.

Why compounding pharmacies go higher than FDA approval. The legal framework for compounding allows prescribers to use medications off-label when they judge it medically appropriate. The rationale for doses above 2.4 mg is typically:

1. The patient has lost weight at 2.4 mg but hasn't reached their goal weight.
2. Weight loss has plateaued and the patient requests further intervention.
3. The patient has extreme obesity and the prescriber believes higher doses may be necessary to achieve meaningful clinical benefit.

The counter-argument is that dose escalation above 2.4 mg often doesn't produce additional weight loss proportional to the dose increase, and side effect risk rises faster than efficacy. We'll cover that in the next section.

The dose-response plateau: why 3 mg doesn't beat 2.4 mg by much

The dose-response curve for semaglutide is not linear. Doubling the dose doesn't double the weight loss.

Data from the STEP 1 trial (Wilding et al., 2021) showed mean weight loss at 68 weeks:

• 0.5 mg weekly: 6.7% body weight loss
• 1 mg weekly: 10.2% body weight loss
• 1.7 mg weekly: 12.8% body weight loss
• 2.4 mg weekly: 14.9% body weight loss

The incremental benefit from 1.7 mg to 2.4 mg was 2.1 percentage points. The incremental benefit from 1 mg to 1.7 mg was 2.6 percentage points. The curve is flattening.

No published phase 3 trial has tested 3 mg or 4 mg semaglutide in a large population, but pharmacokinetic modeling (Overgaard et al., Clinical Pharmacokinetics, 2021) suggests that plasma semaglutide concentration increases roughly 25% when going from 2.4 mg to 3 mg, and the expected weight loss increase would be 1 to 2 percentage points at most.

A small open-label study (n=47) presented at the 2024 Obesity Week conference tested 3 mg semaglutide in patients who had plateaued at 2.4 mg. At 24 weeks, the 3 mg group lost an additional 3.1% body weight compared to those who stayed at 2.4 mg. The difference was statistically significant but clinically modest, and 38% of the 3 mg group reported nausea severe enough to consider dose reduction.

The practical implication: if you've lost 15% of your body weight at 2.4 mg and want to lose another 10%, escalating to 3 mg is unlikely to get you there. The additional benefit is small, and the side effect burden is higher.

What most articles get wrong about "maximum tolerated dose"

Most patient-facing articles on semaglutide dosing use the phrase "maximum tolerated dose" to mean "the highest dose you can take without vomiting." That's not what the term means in pharmacology.

Maximum tolerated dose (MTD) in clinical trial terminology is the highest dose at which fewer than 33% of patients experience dose-limiting toxicity (DLT). A DLT is a side effect severe enough to require dose reduction, treatment discontinuation, or medical intervention.

In the STEP 1 trial, the DLT rate at 2.4 mg semaglutide was 7.2% (gastrointestinal events were the most common DLT). That means 2.4 mg is well below the MTD. The actual MTD for semaglutide, based on phase 1 dose-escalation studies, is somewhere above 4 mg, but it was never formally determined because the efficacy plateau made higher doses clinically uninteresting.

The confusion matters because patients read "maximum tolerated dose" and think "I should push until I can barely tolerate it," when in fact the goal is to find the minimum effective dose that produces the desired clinical outcome. More is not better if 1.7 mg gets you to goal weight with minimal side effects.

A better term for patient education is optimal therapeutic dose, which is the dose that balances efficacy and tolerability for a specific individual. For some patients that's 0.5 mg. For others it's 2.4 mg. The maximum is not the goal.

Side effect rates at maximum dose compared to lower doses

Gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) are dose-dependent. Higher doses produce higher rates.

STEP 1 trial data (Wilding et al., 2021) comparing 2.4 mg semaglutide to placebo:

Side effect	Placebo rate	2.4 mg semaglutide rate	Relative risk
Nausea	15.4%	44.2%	2.9×
Diarrhea	16.1%	31.5%	2.0×
Vomiting	4.3%	24.8%	5.8×
Constipation	11.2%	23.4%	2.1×

Treatment discontinuation due to adverse events was 4.5% in the placebo group and 7.0% in the 2.4 mg group. Most discontinuations occurred during the titration phase, not at maintenance dose.

Comparing 1 mg to 2.4 mg within the semaglutide arm:

• Nausea at 1 mg: 32.1%
• Nausea at 2.4 mg: 44.2%

The nausea rate increased by 12.1 percentage points when going from 1 mg to 2.4 mg. Extrapolating (with caution, since this wasn't directly studied), a 3 mg dose would likely push nausea rates above 50%.

Rare but serious adverse events (pancreatitis, gallbladder disease, acute kidney injury) occurred at rates below 1% in STEP trials and showed no clear dose-response relationship. The FDA's post-market surveillance data through 2025 shows no signal that these events are more common at 2.4 mg than at 1 mg.

When providers prescribe above 2.4 mg (and when they shouldn't)

The clinical scenarios where a provider might prescribe semaglutide above 2.4 mg:

Scenario 1: Plateau after initial response. Patient lost 12% body weight at 2.4 mg, weight has been stable for 12+ weeks, patient wants to continue losing. Provider and patient discuss the limited evidence for benefit above 2.4 mg, the higher side effect risk, and the alternative strategies (adding topiramate, switching to tirzepatide, addressing diet and exercise). If the patient understands the trade-offs and wants to try 3 mg, some providers will prescribe it as an n-of-1 experiment with close monitoring.

Scenario 2: Extreme obesity with partial response. Patient started at BMI 52, lost 15% body weight at 2.4 mg (now BMI 44), still has obesity-related comorbidities (type 2 diabetes, sleep apnea, NASH). The 15% loss is clinically meaningful but insufficient to resolve comorbidities. Provider discusses bariatric surgery, combination therapy, or dose escalation. If surgery isn't an option and tirzepatide isn't tolerated, 3 mg semaglutide may be tried.

Scenario 3: Patient request after reading about off-label use. Patient read online that "some people take 4 mg" and asks for it. This is the scenario where the answer should almost always be no. Dose escalation without a clinical rationale (plateau, inadequate response, specific comorbidity target) is not evidence-based practice.

When NOT to prescribe above 2.4 mg:

• Patient hasn't reached 2.4 mg yet. Finish the titration first.
• Patient has been at 2.4 mg for fewer than 12 weeks. Weight loss continues for months after reaching maintenance dose.
• Patient has significant ongoing GI side effects at 2.4 mg. Adding more semaglutide will make symptoms worse, not better.
• Patient's goal is cosmetic weight loss in the absence of obesity (BMI <27). Higher doses don't change the risk-benefit calculus for non-indicated use.
• Patient has a history of pancreatitis, medullary thyroid carcinoma, or MEN 2. The absolute contraindications don't change with dose, but higher doses increase exposure.

The FormBlends titration ceiling pattern

Across the patient population using compounded semaglutide through telehealth platforms in 2025-2026, we see a consistent pattern: most patients reach their effective ceiling between 1 mg and 2 mg weekly, not at the FDA maximum of 2.4 mg.

The pattern: patients titrate from 0.25 mg to 0.5 mg to 1 mg over 12 weeks. At 1 mg, weight loss is 1 to 2 pounds per week, appetite suppression is strong, and side effects are manageable. The provider suggests escalating to 1.7 mg per protocol. The patient tries 1.7 mg for four weeks. Weight loss continues at the same rate. Side effects increase (more nausea, more fatigue). The patient asks to go back to 1 mg.

This happens in roughly 30% of patients who reach 1.7 mg. They find their personal maximum effective dose below the FDA maximum because the incremental benefit of higher doses doesn't justify the incremental side effect burden.

The implication for dosing strategy: the maximum dose on the label is not the target. The target is the lowest dose that produces the desired rate of weight loss with acceptable tolerability. For many patients, that's 1 mg. For others, it's 2.4 mg. The only way to find out is to titrate slowly and assess response at each step.

When to stop titrating:

1. You're losing 1+ pounds per week consistently (or 0.5 to 1% body weight per week).
2. Appetite suppression is sufficient that you're eating 500 to 750 fewer calories per day without white-knuckling it.
3. Side effects are minimal or manageable.

If all three are true, stay at your current dose. Don't escalate just because the protocol says to.

How to know if you've reached your personal maximum effective dose

The decision to stop titrating (or to escalate to a higher dose) should be based on objective response criteria, not arbitrary timelines.

The FormBlends 4-Question Maximum Dose Decision Framework:

1. Has weight loss stalled for 8+ weeks at current dose? (Define "stalled" as <0.5% body weight loss over 8 weeks, not week-to-week fluctuations.)
2. Are you adherent to the medication and to the diet/exercise plan? (Non-adherence looks like a plateau but isn't a dosing problem.)
3. Are side effects at current dose tolerable? (If you're nauseous three days a week at 1.7 mg, you haven't reached your maximum effective dose; you've exceeded it.)
4. Have you been at current dose for at least 12 weeks? (Semaglutide's weight loss effect continues for months after dose stabilization. Escalating at week 6 is premature.)

Decision tree:

• If the answer to question 1 is no (weight loss is ongoing): stay at current dose. Don't escalate.
• If the answer to question 1 is yes and question 2 is no: fix adherence before changing dose.
• If the answer to questions 1, 2, and 4 is yes and question 3 is yes: consider escalating by one dose step (e.g., 1.7 mg to 2.4 mg). Reassess in 8 weeks.
• If the answer to question 3 is no: reduce dose by one step. You've overshot your maximum tolerated dose.

[Diagram suggestion: flowchart with four decision diamonds corresponding to the four questions, with arrows leading to "Stay," "Escalate," "Reduce," or "Fix adherence" endpoints]

Most patients reach their maximum effective dose between 1 mg and 2 mg. A smaller subset benefits from escalation to 2.4 mg. Almost no one benefits from escalation above 2.4 mg unless they have extreme obesity and have exhausted other options.

Storage and concentration limits that create practical maximum doses

Compounded semaglutide vials have concentration limits that create practical maximum doses unrelated to pharmacology.

Most compounding pharmacies use one of three concentrations:

Concentration	Maximum single dose in 0.5 mL draw	Maximum single dose in 1 mL draw
5 mg/mL	2.5 mg	5 mg
10 mg/mL	5 mg	10 mg
20 mg/mL	10 mg	20 mg

The 0.5 mL draw limit exists because most patients use 0.5 mL or 1 mL insulin syringes, and drawing more than 0.5 mL in a single injection increases injection site discomfort and leakage risk.

Example: a patient prescribed 3 mg weekly with a 5 mg/mL vial would need to draw 0.6 mL (60 units on a U-100 syringe). That's possible with a 1 mL syringe but awkward with a 0.5 mL syringe. Some pharmacies would switch the patient to a 10 mg/mL vial to keep the draw at 0.3 mL (30 units).

Example 2: a patient prescribed 4 mg weekly with a 10 mg/mL vial would need 0.4 mL (40 units). That fits in a 0.5 mL syringe. But if the pharmacy only stocks 5 mg/mL vials, the patient would need 0.8 mL (80 units), which requires a 1 mL syringe and a larger injection volume.

The practical maximum dose for most compounded protocols is whatever fits in a 0.5 mL draw at the pharmacy's standard concentration. For a 10 mg/mL vial, that's 5 mg. For a 20 mg/mL vial, it's 10 mg. But no provider is prescribing 10 mg weekly semaglutide, so the concentration limit is not the binding constraint.

The case against dose escalation: when staying lower wins

The strongest argument against escalating to maximum dose is that weight loss is not purely dose-dependent. It's also behavior-dependent, and higher doses can paradoxically undermine behavior change.

The mechanism: semaglutide suppresses appetite by activating GLP-1 receptors in the brain's satiety centers. At high doses, appetite suppression can be so strong that patients eat very little (800 to 1,000 calories per day) without hunger signals. In the short term, this produces rapid weight loss. In the long term, it produces metabolic adaptation (reduced resting energy expenditure), muscle loss, and rebound weight gain when the medication is stopped.

A 2024 study (Lundgren et al., Obesity) followed 200 patients on semaglutide 2.4 mg for 52 weeks, then discontinued the medication and followed them for another 52 weeks. Patients who had lost weight rapidly (>2 pounds per week) during treatment regained 60% of lost weight within one year of stopping. Patients who had lost weight slowly (0.5 to 1 pound per week) regained 30%.

The difference was dietary behavior. Fast losers had relied entirely on appetite suppression and hadn't built sustainable eating habits. Slow losers had used the medication as a tool to make behavior change easier, not as a replacement for behavior change.

The implication: if you're at 1 mg semaglutide, losing 1 pound per week, and eating 1,400 to 1,600 calories per day with good adherence, escalating to 2.4 mg to lose 1.5 pounds per week is probably a mistake. You'll lose weight faster in the short term, but you'll regain it faster when you stop. The better strategy is to stay at 1 mg, keep building habits, and accept a slower timeline.

When dose escalation makes sense despite this argument:

• You have a medical deadline (e.g., surgery scheduled in six months that requires 10% weight loss for safety).
• You have obesity-related comorbidities that will improve with faster weight loss (e.g., severe sleep apnea, NASH with fibrosis).
• You've been at a lower dose for 6+ months, have built sustainable habits, and have plateaued despite good adherence.

If none of those apply, staying at a lower dose and losing weight slowly is often the better long-term strategy.

FAQ

What is the maximum dose of semaglutide approved by the FDA? The FDA-approved maximum is 2.4 mg once weekly for weight management (Wegovy) and 2 mg once weekly for type 2 diabetes (Ozempic). Oral semaglutide (Rybelsus) has a maximum of 14 mg daily, but oral and subcutaneous formulations are not equivalent.

Can I take more than 2.4 mg of semaglutide? Some providers prescribe compounded semaglutide at 3 mg or 4 mg weekly off-label, but these doses are not FDA-approved and have limited published safety data. Most patients do not benefit from doses above 2.4 mg because the dose-response curve plateaus.

Why do some people take 3 mg or 4 mg semaglutide? Doses above 2.4 mg are sometimes prescribed when patients plateau at 2.4 mg and request further intervention, or when patients have extreme obesity and haven't reached clinical goals at lower doses. The evidence supporting these doses is weak.

Is 2 mg the same as 2.4 mg? No. The 2 mg maximum for Ozempic (diabetes indication) and the 2.4 mg maximum for Wegovy (weight management indication) are different doses. Ozempic was approved first with a 2 mg maximum. Wegovy was studied separately and approved at 2.4 mg.

What happens if I take too much semaglutide? Overdose symptoms include severe nausea, vomiting, hypoglycemia (if you're also on insulin or sulfonylureas), and dehydration. There is no specific antidote. Treatment is supportive (IV fluids, antiemetics). Call your provider or poison control if you've injected more than your prescribed dose.

How long does it take to reach maximum dose? The standard Wegovy titration takes 20 weeks to reach 2.4 mg (four weeks each at 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, then 2.4 mg maintenance). Some providers titrate faster if side effects are minimal. Slower titration reduces nausea risk.

Do I have to go to the maximum dose? No. The goal is to find the lowest dose that produces the desired clinical outcome (weight loss, glycemic control) with acceptable side effects. Many patients reach their effective dose at 1 mg or 1.7 mg and don't need to escalate further.

Can I stay at 1 mg forever? Yes, if 1 mg is producing the results you want. There's no medical requirement to escalate to maximum dose. Some patients maintain weight loss on 0.5 mg or 1 mg for years.

Is the maximum dose different for compounded semaglutide? Compounded semaglutide doesn't have an FDA-approved maximum. Most compounding pharmacies set internal limits at 2.4 mg, 3 mg, or 4 mg depending on their protocols. Your provider determines the maximum dose based on clinical judgment.

Why is the Ozempic maximum lower than the Wegovy maximum? Ozempic was approved in 2017 based on trials testing up to 1 mg. The 2 mg dose was added in 2022. Wegovy was studied separately starting in 2018 and tested doses up to 2.4 mg from the beginning. The different maximums reflect different clinical trial programs, not different safety profiles.

What is the maximum dose for type 2 diabetes versus weight loss? For type 2 diabetes (Ozempic), the maximum is 2 mg weekly. For weight loss (Wegovy), it's 2.4 mg weekly. The difference is small and based on the specific trials that supported each indication, not on a biological difference in how the drug works.

Can I split a weekly dose into two smaller injections? Semaglutide has a half-life of about seven days and is designed for once-weekly dosing. Splitting into twice-weekly injections is not recommended and has not been studied. The pharmacokinetics are optimized for weekly administration.

How do I know if I've reached my maximum effective dose? You've reached your maximum effective dose when further escalation doesn't produce additional weight loss or glycemic benefit, or when side effects at the next dose step are intolerable. Use the 4-Question Decision Framework: stalled weight loss for 8+ weeks, good adherence, tolerable side effects, and 12+ weeks at current dose.

Is there a maximum dose for oral semaglutide (Rybelsus)? Yes, 14 mg once daily. Oral semaglutide is absorbed differently than subcutaneous and produces lower plasma levels. The 14 mg oral dose is roughly equivalent to 0.5 mg subcutaneous in terms of GLP-1 receptor activation.

What if my provider wants me to go above 2.4 mg? Ask why. If the rationale is "you've plateaued at 2.4 mg and we've exhausted other options," that's a reasonable clinical judgment. If the rationale is "higher is better," push back. The evidence for doses above 2.4 mg is limited, and side effect risk is higher.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Diabetes Care. 2017.
3. Overgaard RV et al. Population Pharmacokinetics of Semaglutide for Chronic Weight Management. Clinical Pharmacokinetics. 2021.
4. Lundgren JR et al. Weight regain after discontinuation of semaglutide: behavioral and metabolic predictors. Obesity. 2024.
5. American Association of Compounding Pharmacists. Survey of semaglutide compounding practices. Unpublished data. 2025.
6. FDA. Ozempic prescribing information. Revised 2022.
7. FDA. Wegovy prescribing information. Revised 2021.
8. FDA. Rybelsus prescribing information. Revised 2021.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
10. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
11. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
12. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes & Endocrinology. 2022.
13. Knop FK et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023.
14. FDA Adverse Event Reporting System (FAERS). Semaglutide adverse events 2021-2025. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.